# SNTI catalysts: Senti Biosciences Holdings, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/snti/catalysts

> Senti Biosciences Holdings, Inc. (SNTI) has no upcoming catalysts in this calendar. The latest recorded is the SENTI-202 earnings report, May 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Senti Biosciences Holdings, Inc. |
| Ticker | SNTI (Nasdaq) |
| SEC CIK | 1854270 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/snti |

## Cash runway

Cash $6.5M as of 2026-06-30; quarterly burn $14.2M; about 1.4 months of runway at that rate (XBRL company facts, accession 0001628280-26-057110).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [SENTI-202 trial start](https://sec-api.dev/pdufa/senti-202) | SNTI | hematologic malignancies | completed | "In December 2023, our IND application for evaluation of SENTI-202 in patients with hematologic malignancies was cleared by the FDA, and we began dosing patients in an open-label Phase 1 clinical trial in the United States and Australia in the second quarter of 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/snti-20251231.htm)) |
| late 2024 | [SENTI-202 interim data readout](https://sec-api.dev/pdufa/senti-202) | SNTI |  | scheduled | "Initial safety and efficacy data readout remains on-track by year-end 2024 and initial durability data is expected to follow in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm)) |
| November 14, 2024 | [SENTI-202 trial start](https://sec-api.dev/pdufa/senti-202) | SNTI | relapsed/refractory hematologic malignancies | completed | "SENTI-202 for Acute Myeloid Leukemia ("AML"): The Company announced that patient dosing has commenced, and is ongoing, in the Phase 1 clinical trial of SENTI-202 (NCT06325748) for the treatment of relapsed/refractory hematologic malignancies including AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm)) |
| November 14, 2024 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/a20241114ex991earningsrele.htm)) |
| December 2, 2024 | [SENTI-202 interim data readout](https://sec-api.dev/pdufa/senti-202) | SNTI | relapsed/refractory hematologic malignancies | completed, positive | "SOUTH SAN FRANCISCO, Calif., December 2, 2024 - Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer ("CAR-NK") investigational cell therapy, for the treatment of relapsed/refractory ("R/R") hematologic malignancies including acute myeloid leukemia ("AML")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_ex99-1.htm)) |
| December 16, 2024 | [SN301A trial start](https://sec-api.dev/pdufa/sn301a) | SNTI |  | completed | "On December 16, 2024, Senti Biosciences, Inc. (the "Company") issued a press release announcing the first patient dosed in a clinical trial of SN301A in hepatocellular carcinoma in collaboration with Celest Therapeutics (Shanghai) Co. Ltd. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1854270/000185427024000128/snti-20241216.htm)) |
| March 20, 2025 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/a202503208kex991.htm)) |
| April 28, 2025 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Announces certain preliminary first quarter 2025 financial results and provides pipeline update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/ex992_snti2025clinicaldata.htm)) |
| May 6, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/ex991snti2025q125earningsr.htm)) |
| August 7, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/ex991snti2025q125earningsr.htm)) |
| late 2025 | [SENTI-202 topline data readout](https://sec-api.dev/pdufa/senti-202) | SNTI |  | scheduled | "Enrollment is ongoing in the expansion cohort at the RP2D, with topline data expected before the end of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1854270/000162828025052125/snti-20250930.htm)) |
| November 13, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/ex991snti2025q325earningsr.htm)) |
| March 27, 2026 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/ex991sntiq425earningsrelea.htm)) |
| May 14, 2026 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/ex991sntiq126earningsrelea.htm)) |

## Drugs

- [SENTI-202](https://sec-api.dev/pdufa/senti-202): hematologic malignancies, relapsed/refractory hematologic malignancies, relapsed/refractory
- [SN301A](https://sec-api.dev/pdufa/sn301a): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/snti/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SNTI catalysts: Senti Biosciences Holdings, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/snti/catalysts

```bibtex
@misc{secapidev_companies_snti_catalysts_20261116,
  title        = {SNTI catalysts: Senti Biosciences Holdings, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/snti/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_snti_catalysts_20261116","title":"SNTI catalysts: Senti Biosciences Holdings, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/snti/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
